J&J Says Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival In EGFR Exon 20 Insertion NSCLC
Johnson & Johnson NYSE:JNJ
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.